Previous 10 | Next 10 |
China's National Medical Products Administration approved Pfizer's Paxlovid, an oral COVID-19 therapy for adults who have mild-to-moderate COVID-19 and are at high risk of progressing to severe disease. The approval is conditional, based on Pfizer providing additional data. Shanghai S...
Legend Biotech (NASDAQ:LEGN) has reported preliminary results for 2021, expecting loss of ~$365.3M to $397.4M and adj. loss of $335.8M to $364.7M. As of Dec. 31, 2021, Legend Biotech had ~$688.9M of cash and cash equivalents. R&D expenses are estimated between ~$297.9M-$321.8M, mainly cau...
Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global, clinical-stage biotechnology company developing and manufacturing novel therapies, today in conjunction with an announcement to be issued by Legend Biotech’s majority shareholder, GenScript Biotech Corporation,...
Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE:JNJ), has partnered with Remix Therapeutics, a biotech company developing small molecule therapies designed to reprogram RNA processing. Per the terms, Janssen will have access to three specif...
Legend Biotech (NASDAQ:LEGN) is trading ~6% lower in the pre-market on Tuesday after the company announced that the U.S Food and Drug Administration (FDA) imposed a clinical hold on its Phase 1 trial for LB1901. An autologous chimeric antigen receptor T-cell (CAR-T) therapy, LB1901,...
Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global, clinical-stage biotechnology company developing and manufacturing novel therapies, today announced that on Friday, February 11, 2022, the company was informed by the U.S Food and Drug Administration (FDA) via e-mail c...
Legend Biotech (NASDAQ:LEGN) announced the achievement of two milestones under its collaboration with Janssen Biotech of Johnson & Johnson (NYSE:JNJ) for cilta-cel. Also called ciltacabtagene autoleucel, cilta-cel is an experimental B-cell maturation antigen (BCMA)-directed chimeric antig...
Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global, clinical-stage biotechnology company developing and manufacturing novel therapies, has achieved two milestones under its collaboration agreement with Janssen Biotech, Inc. for ciltacabtagene autoleucel (cilta-cel), re...
U.S.-listed Chinese biotech companies are trading lower after the U.S. commerce department added life-sciences company, WuXi Biologics (OTCPK:WXXWY -13.5%) (OTCPK:WXIBF -22.6%), to its “unverified” list for exporters. Notable decliners include I-Mab (IMAB -5.7%) and BeiGene (BGN...
Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global, clinical-stage biotechnology company developing and manufacturing novel therapies, will virtually participate in the 40 th Annual J.P. Morgan Healthcare Conference. Ying Huang, PhD, CEO and CFO of Legend Biotech, ...
News, Short Squeeze, Breakout and More Instantly...
Legend Biotech Corporation Company Name:
LEGN Stock Symbol:
NASDAQ Market:
Legend Biotech Corporation Website:
SOMERSET, N.J., July 10, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Friday, August 9, 2024, to review second-quarter 2024 results. During the webcast and confe...
SOMERSET, N.J., July 02, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today positive overall survival results from CARTITUDE-4, an ongoing, global randomized, open-label Phase 3 study evaluating the efficacy and sa...
2024-06-20 17:01:11 ET USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – June 20,2024 – USA News Group News Commentary – The potential threat of cancer looms for everyone, but now new studies are revealing an increased number o...